

This provisional PDF corresponds to the article as it appeared upon acceptance.

A copyedited and fully formatted version will be made available soon.

The final version may contain major or minor changes.

## **COVID-19 mortality rates in the European Union, Switzerland, and the UK: effect of timeliness, lockdown rigidity, and population density**

Alberto G GERLI, Stefano CENTANNI, Monica MIOZZO, J. Christian VIRCHOW, Giovanni SOTGIU, G. Walter CANONICA, Joan B SORIANO

*Minerva Medica* 2020 Jun 02

DOI: 10.23736/S0026-4806.20.06702-6

Article type: Original Article

© 2020 EDIZIONI MINERVA MEDICA

Article first published online: June 2, 2020

Manuscript accepted: May 28, 2020

Manuscript received: May 27, 2020

Subscription: Information about subscribing to Minerva Medica journals is online at:

<http://www.minervamedica.it/en/how-to-order-journals.php>

Reprints and permissions: For information about reprints and permissions send an email to:

[journals.dept@minervamedica.it](mailto:journals.dept@minervamedica.it) - [journals2.dept@minervamedica.it](mailto:journals2.dept@minervamedica.it) - [journals6.dept@minervamedica.it](mailto:journals6.dept@minervamedica.it)

# COVID-19 mortality rates in the European Union, Switzerland, and the UK: effect of timeliness, lockdown rigidity, and population density

Alberto G. Gerli, MSc,<sup>1</sup> Stefano Centanni, MD,<sup>2</sup> Monica R. Miozzo, PhD,<sup>3</sup> J. Christian Virchow, MD,<sup>4</sup> Giovanni Sotgiu, MD,<sup>5</sup> G. Walter Canonica, MD,<sup>6</sup> Joan B. Soriano, MD.<sup>7,8</sup>  
([ORCID 0000-0001-9740-2994](https://orcid.org/0000-0001-9740-2994))

<sup>1</sup> Management Engineering Tourbillon Tech srl Padova, Italy

<sup>2</sup> Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di Milano, Milano, Italy

<sup>3</sup> Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

<sup>4</sup> Departments of Pneumology, Intensive Care Medicine, Center for Internal Medicine, Universitätsmedizin Rostock, Germany

<sup>5</sup> Clinical Epidemiology and Medical Statistics Unit, Department of Medical, Surgical, Experimental Sciences, University of Sassari, Sassari, Italy

<sup>6</sup> Allergy & Asthma Clinic, Humanitas University & Research Hospital IRCCS, Milano, Italy

<sup>7</sup> Hospital Universitario de la Princesa, Madrid, Spain

<sup>8</sup> Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

## Address for correspondence:

Dr. Joan B Soriano

Hospital Universitario de la Princesa, Servicio de Neumología, 6ª planta, Diego de León 62, 28006-Madrid, Spain

**Email:** [jbsoriano2@gmail.com](mailto:jbsoriano2@gmail.com)

**Phone:** +34 6188677690

## Document information

**File name:** EU27plus2 paper to Minerva Medica

**Date:** May 27, 2020

**Illustrations:** One table and three figures (plus two e-figures in an Online Appendix)

**Word count:** 2,137 words

**References:** 28 references

**Journal:** Minerva Medica

<https://www.minervamedicaonlinesubmission.it/?CollectionSetId=26>

**Running title:** COVID-19 mortality in the EU, Switzerland, and the UK

**Declarations**

**Funding:** None

**Conflicts of interest/Competing interests:** All authors declare there are no conflicts of interest to disclose neither directly nor indirectly related with this research

**Ethics approval (include appropriate approvals or waivers):** Not applicable

**Consent to participate (include appropriate statements):** Not applicable

**Consent for publication (include appropriate statements):** Not applicable

**Availability of data and material (data transparency):** Data is available upon formal request

**Code availability (software application or custom code):** Data is available upon formal request

**Authors' contributions:** JBS had the initial idea and drafted the first version. AGG collected all source data, conducted all modelling and statistical analyses. All authors contributed to drafting and interpreting results, and approved the final version of this manuscript. JBS is the guarantor of this research

## Abstract

**Background** To date the European experience with COVID-19 mortality has been different to the observed in China and Asia. We aimed to forecast mortality trends in the 27 countries of the European Union (EU), plus Switzerland and the United Kingdom (UK), where lockdown dates and confinement interventions have been heterogeneous, and to explore its determinants.

**Methods:** We have adapted our predictive model of COVID-19-related mortality, which rested on the observed mortality within the first weeks of the outbreak and the date of the respective lockdown in each country. It was applied in a training set of three countries (Italy, Germany and Spain), and then applied to the EU plus the UK and Switzerland. In addition, we explored the effects of timeliness and rigidity of the lockdown (on a five-step scale) and population density in our forecasts. We report  $r^2$ , and percent variation of expected versus observed deaths, all following TRIPOD guidance.

**Results:** We identified a homogeneous distribution of deaths, and found a median of 24 days after lockdown adoption to reach the maximum daily deaths. Strikingly, cumulative deaths up to April 25<sup>th</sup>, 2020 observed in Europe separated countries in three waves, according to the time lockdown measures were adopted following the onset of the outbreak: after a week, within a week, or even prior to the outbreak ( $r^2=0.876$ ). In contrast, no correlation neither with lockdown rigidity nor population density were observed.

**Conclusions:** The European experience confirms that early, effective interventions of lockdown are fundamental to minimizing the COVID-19 death toll.

**Abstract word count:** 247 words (maximum 250 words)

**Key words:** COVID-19; Europe; Lockdown; Mortality

## Introduction

The unprecedented, rapid spread of SARS-Cov-2 epidemic urgently requires new, timely epidemiological evidence to help mitigate the population burden. Since the safety alert on Tuesday, December 31, 2019 reported in Wuhan, Hubei Province, China due to a cluster of pneumonia of unknown etiology,<sup>1</sup> it took ten days, on January 9, 2020, for China's CDC to report that a novel coronavirus was the causative agent of that local outbreak.<sup>2</sup> Indeed, appropriate epidemiological indicators associated with COVID-19 are necessary steps to reduce the negative consequences of this ongoing pandemic.<sup>3,45</sup> Several countries responded belatedly, with considerable heterogeneity and with different political and healthcare approaches to containment.<sup>6</sup>

Initially focused on an innovative and robust data mining approach based on Chinese and Italian data to forecast SARS-Cov-2-related mortality,<sup>7</sup> our model concluded that SARS-Cov-2-related mortality is closely correlated to early events after the onset of the outbreak, and to the timing of regional/national interventions on social distancing and lockdown, as well as the occurrence of superspreading events (e.g., Italy, Germany, and Spain).<sup>8</sup>

To date the European COVID-19 mortality trends have been largely different to those observed in China and Asia.<sup>9</sup> We aimed to forecast mortality trends up to May 31<sup>st</sup>, 2020, in the 27 countries of the European Union (EU), plus Switzerland and the United Kingdom (UK), where lockdown timeliness and confinement interventions are highly variable, as well as the effect of that diversity.

## Methods

Publicly available data from official data sources on the timing and distribution of deaths related with COVID-19 by country were retrieved.<sup>10,11,12</sup> Our algorithm was fed with data up to April 25<sup>th</sup>, 2020, and forecasted mortality up to May 31<sup>st</sup>, 2020.

Our initial model was proven to be accurate in predicting COVID-19 deaths in Italy, Germany, and Spain.<sup>7</sup> This was adapted to forecast COVID-19 mortality in 29 European countries (EU, plus Switzerland and the UK). The model takes into consideration the following variables: the observed mortality distribution within the first 17 days of the outbreak and the date of the national lockdown. This was modelled firstly with a 3<sup>rd</sup> degree polynomial curve, secondly by a five-parameter logistic (5PL) asymmetrical sigmoidal curve following a parametric growth. Its application was performed to a training set of the 29 countries, both individually and aggregated. Given that lockdown rigidity and population density could be considered determinant factors affecting the death toll, we explored their effects on the forecasts.

Lockdown rigidity was defined by five steps based on increasing levels of closing of commercial and non-commercial activities, namely: 0 without any measures other than travelling ban; 1 gathering ban only; 2 schools closing; 3 plus closure of restaurants and bars; 4 also including non-essential shops; and 5 lockdown extended to non-essential factories. Lockdown dates were chosen when at least a lockdown step 3 was adopted; if no such lockdown occurred, we selected the date where the next stricter lockdown was adopted. Outbreak onset was defined as the first day when at least one death was recorded with  $\geq 3$  deaths in the following two days. Of note, Cyprus, Latvia, and Slovakia (respectively 19, 12, and 17 deaths) were not included in the predictive model because of not fulfilling this definition during the first 17 days of outbreak.

Being our algorithm a test prediction model for individual prognosis or diagnosis,  $r^2$  and variation of expected versus observed deaths (percentage) were reported following Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) guidance.<sup>13</sup>

## Results

Information on the national distribution of deaths within the first 17 days of the outbreak, lockdown date and rigidity, and days from lockdown to the onset of the epidemic was obtained in 29 European countries ([Table 1](#)).

A homogeneous distribution of observed versus expected deaths was found, with a median of 24 days after lockdown adoption to reach maximum daily deaths in all EU countries, the UK, and Switzerland, with an arithmetic  $r^2$  of 0.917, ([Figure 1a](#)) and an aggregated  $r^2$  of 0.998 ([Figure 1b](#)).

Cumulative deaths up to April 25<sup>th</sup>, 2020, showed a pattern which depends on the timing of the lockdown adoption ([Figure 2](#)). Namely, countries which implemented lockdown after a week from outbreak onset (i.e., 9 days in the UK, 10 days in Spain, 12 days in France, or 15 days in Italy) experienced the greatest mortality, ranging from 20,319 up to 26,384 deaths, whereas countries which implemented lockdown within a week experienced an intermediate mortality, from 601 up to 6,917 deaths; on the contrary, those countries which implemented lockdown before the onset of the national outbreak (i.e., -30 days in Slovakia, -20 days in Latvia, or -19 days in Bulgaria) experienced the lowest mortality, from 4 up to 536 deaths.

Cumulative deaths up to April 25<sup>th</sup>, 2020, computed in EU countries, Switzerland, and the UK were tightly linked to the timing of the lockdown adoption ([Figure 3](#)), with a high correlation ( $r^2=0.876$ ), with an exponential fitting.

Finally, we explored the effect of lockdown rigidity and population density on these trends. We found no correlation of neither lockdown rigidity with number of days needed to reach the maximum daily deaths, nor of population density and observed deaths. ([Online Appendix, eFigures I and II](#)).

## 180 Discussion

181 Our study highlights the key role played by early events and earlier interventions in the  
182 reduction of COVID-19 mortality. Regrettably, late adoption of effective national  
183 lockdown was associated with a higher mortality, particularly if the lockdown occurred  
184 after one week from the outbreak onset (first day when at least one death occurred  
185 with at least three deaths in the following two days). This suggests that for non-  
186 European countries (not included in this analysis), where the spread has been slower  
187 or later, delaying or avoiding lockdown interventions might be detrimental.

## 188 Literature review on COVID-19 forecasting

189 A number of modelling and forecasting tools quantifying the future COVID-19 burden  
190 are available elsewhere.<sup>14,15,16,17,18,19,20</sup>  
191 Sebastiani, et al.,<sup>20</sup> described the trends of Covid-19 spread in Italy, studying the  
192 positive cases cumulative incidence, and found similar conclusions of our study about  
193 the importance of early containment measures to counteract the epidemic diffusion.  
194 We accept the nihilistic conclusion that all outbreak forecasting is subject to errors;  
195 however, we followed TRIPOD to cover our model development when limited data  
196 were available.<sup>21</sup> We envisage that the eventual pooling of estimates from  
197 independent forecasts performed by independent groups will be the closest to  
198 reality,<sup>22,23</sup> likely to be observed both in the immediate- and distant future of the  
199 ongoing COVID-19 outbreak.<sup>24</sup>

## 202 Strengths and limitations

203 The strengths of our model are its virtual immediacy; parsimony, being the algorithm  
204 based on two entry variables, namely dates of outbreak onset and lockdown, and  
205 distribution of deaths within the first 17 days from that date; and easy replicability and  
206 testing. However, a number of limitations must be discussed: up-to-date, official  
207 counting and distribution of deaths by country were retrieved. But, accuracy and  
208 completeness of national statistics, reluctance on data sharing, heterogeneous  
209 definitions, changes in coding practices, and other technical issues can affect the  
210 reliability of country estimates.<sup>25</sup> Without a established lockdown date no forecasting  
211 curve can be fit. No significant correlations were found when COVID-related lockdown  
212 rigidity and population density were included in the analysis; however, more specific  
213 analyses might target any population effect of these crucial variables.

## 215 Implications of our research

216 SARS-Cov-2 is a novel virus and COVID-19 is still a mostly unknown disease, with  
217 already differences compared with other coronavirus-related medical conditions (e.g.:  
218 SARS and MERS).<sup>26</sup> Many enigmas remain at both the individual and societal level of  
219 the COVID-19 outbreak, including how factors such as weather and climate, herd  
220 immunity, individual and ethnic susceptibility, health systems quality, new treatments  
221 and therapeutic regimes, and effective vaccines could affect globally and nationally the  
222 COVID-19 epidemic. Our research may have public health implications which can help  
223 mitigate the national COVID-19 burden. Individual country leaders such as in Brazil,  
224 Nicaragua<sup>27</sup> or elsewhere, have actively neglected lockdown initiatives suggested by  
225 the WHO and implemented in many countries. New models might take into account



the interaction of demography and current age-specific mortality for COVID-19, as well as social distancing and other containment policies, age composition of local and national contexts, and intergenerational interactions. We join the call for countries to provide case and fatality data disaggregated by age and gender to improve real-time targeted forecasting of hospitalization and critical care needs.<sup>28</sup> Beyond Europe, given intrinsic difficulties and variable political decisions against this pandemic, the expected death toll might become significantly higher.

## Conclusions

Early adoption of effective lockdown measures in European countries was correlated with a reduced death toll, and was most effective in those countries which implemented them before the onset of the outbreak.

**Table 1.** COVID-19-related containment and lockdown measurements with dates in the 27 European Union countries, plus Switzerland and the UK

Country	17 days range	Lockdown date	Lockdown rigidity	R <sup>2</sup>	Delta
Austria	21/03 - 06/04	17/03	4	0.964	-8.0%
Belgium	16/03 - 01/04	18/03	4	0.988	-0.2%
Bulgaria	01/04 - 17/04	13/03	4		-25.5%
Croatia	02/04 - 18/04	17/03	4	0.734	-14.8%
Cyprus	27/03 - 12/04	15/03	0		
Czechia	24/03 - 09/04	16/03	4	0.967	4.6%
Denmark	19/03 - 04/04	13/03	3	0.931	0.2%
Estonia	31/03 - 16/04	13/03	2	0.536	-8.7%
Finland	25/03 - 10/04	16/03	2	0.752	-53.8%
France	05/03 - 21/03	17/03	4	0.997	-6.1%
Germany	13/03 - 29/03	16/03	3	0.957	-4.8%
Greece	21/03 - 06/04	10/03	4	0.893	4.6%
Hungary	20/03 - 05/04	16/03	2.5	0.878	-46.3%
Ireland	22/03 - 07/04	27/03	5	0.974	-11.1%
Italy	23/02 - 10/03	09/03	5	0.993	6.0%
Latvia	03/04 - 19/04	14/03	1		
Lithuania	04/04 - 20/04	12/03	2		-9.8%
Luxembourg	26/03 - 11/04	16/03	2	0.803	27.1%
Malta	08/04 - 24/04	16/03	3		
Netherlands	13/03 - 29/03	13/03	1	0.953	10.8%
Poland	23/03 - 08/04	20/03	3	0.928	11.3%
Portugal	18/03 - 03/04	18/03	4	0.989	11.6%
Romania	22/03 - 07/04	24/03	3	0.972	-19.8%
Slovakia	15/04 - 01/05	16/03	4		
Slovenia	25/03 - 10/04	16/03	3	0.956	8.6%
Spain	05/03 - 21/03	15/03	5	0.978	31.2%
Sweden	16/03 - 01/04	17/03	1	0.976	-4.9%
Switzerland	13/03 - 29/03	16/03	4	0.992	18.3%
UK	14/03 - 30/03	23/03	4	0.986	7.3%

**Figure 1.** Robustness of the predictive model to forecast COVID-19-related mortality in the EU, Switzerland and the UK

**Figure 1a)** Expected vs observed percent death ratio associated with days since outbreak onset in each EU country, Switzerland and the UK

**Figure 1a footnote.** The x axis represents the number of days needed to reach a maximum daily deaths peak after lockdown adoption (as per our algorithm). The y axis represents the death ratio percentage: (expected – observed)/observed. For each country, we mined data from the first 17 days since the onset of the outbreak (first COVID-19 deaths detected) to prove correlation and robustness of the model from day 18 onwards (histograms).

The red line shows the arithmetic average of the values of all countries, which intercepts y axis in the interval (24 - 25 days), closer to 24 days. The blue line shows the arithmetic average of all absolute values of all countries, which has the lower value with 24 days.

**Figure 1b)** Observed and expected cumulative deaths in all 29 European countries

**Figure 1b footnote:** Observed and expected aggregated data for the EU27, Switzerland and the UK. The grey line shows expected deaths assuming 24 days, according to Figure 1a.

**Figure 2.** Map of cumulative deaths up to April 25<sup>th</sup>, 2020 observed in European countries (EU, Switzerland and the UK) according to the timing of the lockdown adoption.

a) After one week; b) within a week; and c) before outbreak onset

**Figure 3.** Correlation of cumulative deaths up to April 25<sup>th</sup>, 2020 observed in European countries (EU, Switzerland and the UK) according to the timing of the lockdown adoption ( $r^2 = 0.878$ )

## Online Appendix:

**Online Appendix eFigure I.** Lack of direct correlation among lockdown rigidity (five steps) and deaths and days to reach daily peak.

**Online Appendix eFigure II.** Association of population density and total population with observed deaths ( $r^2 = 0.626$ ).

287 **References:**

- <sup>1</sup> Emergencies preparedness, response. Pneumonia of unknown cause – China [available at <https://www.who.int/csr/don/05-january-2020-pneumonia-of-unknown-cause-china/en/>, accessed on January 5, 2020].
- <sup>2</sup> Mahase E. Coronavirus: UK screens direct flights from Wuhan after US case. *BMJ*. 2020 Jan 22;368:m265. doi: 10.1136/bmj.m265.
- <sup>3</sup> Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; 382(8): 727-33.
- <sup>4</sup> Douglas M, Katikireddi SV, Taulbut M, McKee M, McCartney G. Mitigating the wider health effects of covid-19 pandemic response. *BMJ*. 2020 Apr 27;369:m1557.
- <sup>5</sup> Editorial. COVID-19 puts societies to the test. *Lancet Public Health* 2020; 5 (ISSUE 5), E235, May 01, 2020.
- <sup>6</sup> Horton R. Offline: COVID-19—what countries must do now. *Lancet* 2020; 395:1100.
- <sup>7</sup> Gerli, AG, Centanni, S, Miozzo, MR, Sotgiu, G Early prediction of COVID-19-related deaths and infections fitting worldwide. *The International Journal of Tuberculosis and Lung Disease*. In press
- <sup>8</sup> Sotgiu G, Gerli AG, Centanni S, Miozzo M, Canonica GW, Soriano JB, Virchow C. Advanced forecasting of SARS-CoV-2 related deaths in Italy, Germany, Spain, and New York State. *Allergy*. 2020 Apr 18. doi: 10.1111/all.14327.
- <sup>9</sup> Steffens I. A hundred days into the coronavirus disease (COVID-19) pandemic. *Euro Surveill*. 2020 Apr;25(14). doi: 10.2807/1560-7917.ES.2020.25.14.2000550.
- <sup>10</sup> Ministerio de Sanidad, Consumo y Bienestar. Situación de COVID-19 en España. Available at: <https://covid19.isciii.es> [accessed on April 26, 2020]
- <sup>11</sup> Dipartimento della Protezione Civile – Comunicati Stampa. Available at: <https://npgeo-corona-npgeo-de.hub.arcgis.com/> [accessed on April 26, 2020]
- <sup>12</sup> Novel Coronavirus (COVID-19) Cases Data. This dataset is part of COVID-19 Pandemic. Available at: <https://data.humdata.org/dataset/novel-coronavirus-2019-ncov-cases> [accessed on April 30, 2020]
- <sup>13</sup> Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Available at <https://www.equator-network.org/reporting-guidelines/tripod-statement/> [accessed on April 10, 2020].
- <sup>14</sup> IHME COVID-19 health service utilization forecasting team. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator days and deaths by US state in the next 4 months. *MedRxiv* 2020.
- <sup>15</sup> Xu B, Gutierrez B, Mekaru S, Sewalk K, Goodwin L, Loskill A, Cohn EL, Hsuen Y, Hill SC, Cobo MM, Zarebski AE, Li S, Wu C-H, Hulland E, Morgan JD, Wang L, O'Brien K, Scarpino SV,

Brownstein JS, Pybus OG, Pigott DM, Kraemer MUG. Epidemiological data from the COVID-19 outbreak, real-time case information. *Scientific Data* 2020;7:106.

<sup>16</sup> García-Basteiro LA, Chaccour C, Guinovart C, Llupià A, Brew J, Trilla A, Plasencia A. Monitoring the COVID-19 epidemic in the context of widespread local transmission. *Lancet Respir Med* 2020;S2213-2600(20)30162-4.

<sup>17</sup> Shojaei S, Pourhoseingholi MA, Ashtari S, Vahedian-Azimi A, Asadzadeh-Aghdahi H, Zali MR. Predicting the mortality due to Covid-19 by the next month for Italy, Iran and South Korea; a simulation study. *Gastroenterol Hepatol Bed Bench*. 2020 Spring;13(2):177-179.

<sup>18</sup> Anastassopoulou C, Russo L, Tsakris A, Siettos C. Data-based analysis, modelling and forecasting of the COVID-19 outbreak. *PLoS One*. 2020 Mar 31;15(3):e0230405. doi: 10.1371/journal.pone.0230405. eCollection 2020.

<sup>19</sup> Zareie B, Roshani A, Mansournia MA, Rasouli MA, Moradi G. A Model for COVID-19 Prediction in Iran Based on China Parameters. *Arch Iran Med*. 2020 Apr 1;23(4):244-248. doi: 10.34172/aim.2020.05.

<sup>20</sup> Sebastiani G, Massa M, Riboli E. Covid-19 epidemic in Italy: evolution, projections and impact of government measures. *Eur J Epidemiol*. 2020 Apr;35(4):341-345. doi: 10.1007/s10654-020-00631-6. Epub 2020 Apr 18.

<sup>21</sup> Sperrin M, Grant SW, Peek N. Prediction models for diagnosis and prognosis in Covid-19. *BMJ*. 2020 Apr 14;369:m1464. doi: 10.1136/bmj.m1464.

<sup>22</sup> van Houwelingen HC. The future of biostatistics: expecting the unexpected. *Stat Med*. 1997 Dec 30;16(24):2773-84.

<sup>23</sup> Hemming K, Bowater RJ, Lilford RJ. Pooling systematic reviews of systematic reviews: a Bayesian panoramic meta-analysis. *Stat Med*. 2012 Feb 10;31(3):201-16. doi: 10.1002/sim.4372. Epub 2011 Oct 3.

<sup>24</sup> Sera F, Armstrong B, Blangiardo M, Gasparrini A. An extended mixed-effects framework for meta-analysis. *Stat Med*. 2019 Dec 20;38(29):5429-5444. doi: 10.1002/sim.8362.

<sup>25</sup> Tsang TK, Wu P, Lin Y, Lau EHY, Leung GM, Cowling BJ. Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study. *Lancet Public Health*. 2020 Apr 21. pii: S2468-2667(20)30089-X. doi: 10.1016/S2468-2667(20)30089-X.

<sup>26</sup> Ceccarelli M, Berretta M, Venanzi Rullo E, Nunnari G, Cacopardo B. Differences and similarities between Severe Acute Respiratory Syndrome (SARS)-CoronaVirus (CoV) and SARS-CoV-2. Would a rose by another name smell as sweet?. *Eur Rev Med Pharmacol Sci*. 2020 Mar;24(5):2781-2783. doi: 10.26355/eurev\_202003\_20551.

<sup>27</sup> Mather TPS, Marin BG, Perez GM, Christophers B, Paiva ML, Oliva R, Hijaz BA, Prado AM, Jarquín MC, Moretti K, Marqués CG, Murillo A, Tobin-Tyler E. Love in the time of COVID-19: negligence in the Nicaraguan response. *Lancet Glob Health*. 2020 Apr 6. pii: S2214-109X(20)30131-5. doi: 10.1016/S2214-109X(20)30131-5.

---

<sup>28</sup> Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, Liu Y, Mills MC. Demographic science aids in understanding the spread and fatality rates of COVID-19. *Proc Natl Acad Sci U S A*. 2020 Apr 16. pii: 202004911. doi: 10.1073/pnas.2004911117. [Epub ahead of print]













